Market Closed - Nyse 16:00:02 2024-05-08 EDT 5-day change 1st Jan Change
10.16 USD -11.88% Intraday chart for Nevro Corp. -2.40% -52.79%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Truist Securities Lowers Nevro's Price Target to $11 From $14, Hold Rating Maintained MT
Piper Sandler Adjusts Nevro's Price Target to $12 From $15, Maintains Underweight Rating MT
Wells Fargo Trims Nevro Price Target to $13 From $14, Maintains Equal Weight Rating MT
Transcript : Nevro Corp., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (NVRO) NEVRO Reports Q1 Revenue $87M, vs. Street Est of $97.9M MT
Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024 CI
Nevro Corp. Announces Resignation of Richard B. Carter as Chief Accounting Officer and Principal Accounting Officer, Effective May 10, 2024 CI
RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating MT
Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating MT
Citigroup Cuts Price Target on Nevro to $16 From $18, Maintains Neutral Rating MT
Nevro 2024 Sales Expected Slightly Below Estimates, RBC Says MT
Wells Fargo Adjusts Price Target on Nevro to $17 From $20, Maintains Equal-Weight Rating MT
Baird Cuts Price Target on Nevro to $19 From $23, Maintains Neutral Rating MT
Oppenheimer Downgrades Nevro to Perform From Outperform, Removes $35 Price Target MT
RBC Lowers Price Target on Nevro to $18 From $20, Keeps Sector Perform Rating MT
Earnings Flash (NVRO) NEVRO Posts Q4 Revenue $116.2M, vs. Street Est of $116M MT
Engaged Capital Enters into Agreement with Nevro Corp CI
Transcript : Nevro Corp., Q4 2023 Earnings Call, Feb 21, 2024
Nevro Corp. Appoints Kirt P. Karros to Board of Directors and Audit Committee of the Board CI
Nevro Corp. Provides Earnings Guidance for the First Quarter and Full Year of 2024 CI
Nevro Corp. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
RBC Downgrades Nevro to Sector Perform From Outperform, Cuts Price Target to $20 From $23 MT
Transcript : Nevro Corp. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 08:15 AM
Sector Update: Health Care Stocks Mixed in Afternoon Trading MT
Nevro to Cut 5% of Workforce in Restructuring, Says Preliminary Q4 Revenue Rose 2% MT
Chart Nevro Corp.
More charts
Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
17
Last Close Price
11.53 USD
Average target price
16.63 USD
Spread / Average Target
+44.26%
Consensus
  1. Stock Market
  2. Equities
  3. NVRO Stock
  4. News Nevro Corp.
  5. Truist Securities Adjusts Price Target on Nevro to $23 From $22, Maintains Hold Rating
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW